Tags » People Places Events

Califf To Leave Duke To Become FDA Deputy Commissioner

The FDA announced today that Duke University cardiologist Robert Califf will be the next FDA Deputy Commissioner for Medical Products and Tobacco. The agency said that Califf will be responsible for the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health and the Center for Tobacco Products.” 10 more words

Policy & Ethics

Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race

Early on Monday Sanofi and Regeneron leapfrogged their rival Amgen to gain leadership in the race to bring a new class of cholesterol drugs to market. 56 more words

Prevention, Epidemiology & Outcomes

Salt, Science, And The American Heart Association's Double Standard

Once again the American Heart Association is sticking by its recommendation that pretty much everyone should consume no more than 1,500 milligrams of sodium each day. 73 more words

Policy & Ethics

Why Doctors, Like Airline Pilots, Should Not Be Completely Trusted. 

I would never get on an airplane if I didn’t feel highly confident that the pilot was fully competent. In order to fly a commercial airplane a pilot has to  undergo rigorous and continuous training and testing. 198 more words

Policy & Ethics

Buried Clinical Trial Data: The Dam Is About to Burst

Two important new developments may mean that many more researchers will soon be able to access and analyze data from many more clinical trials.

… a  120 more words

Policy & Ethics

AstraZeneca Drug Improves Outcomes After Heart Attacks

For the first time a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients one to three years after a heart attack. 74 more words

People, Places & Events

More Turmoil For Troubled Medical Laboratory Company

Problems continue to accumulate for the deeply troubled medical laboratory company Health Diagnostic Laboratory. Following several years of spectacular growth, in which the company grew to $400 million in annual revenue, the company last year began an equally spectacular implosion when it became known that the federal government was investigating the company for giving kickbacks to physicians to use the company’s tests. 65 more words

Policy & Ethics